Changes in Lean Muscle Mass Associated with Neoadjuvant Platinum-Based Chemotherapy in Patients with Muscle Invasive Bladder Cancer
Open Access
- 11 September 2018
- journal article
- research article
- Published by SAGE Publications in Bladder Cancer
- Vol. 4 (4) , 411-418
Abstract
Background: Baseline sarcopenia or severe lean muscle deficiency is independently associated with increased mortality after cystectomy for muscle-invasive urothelial carcinoma of the bladder (MIUC). The impact of chemotherapy on muscle mass in MIUC patients remains undefined Objectives: To describe preoperative changes in body composition in MIUC patients receiving platinum-based neoadjuvant chemotherapy (NC). Methods: Patients with cT2-4 N0-1 M0 UC of the bladder who received NC were identified. Lumbar skeletal muscle index (SMI, cm 2 /m 2 ), visceral adipose index (VAI, cm 2 /m 2 ), and the subcutaneous and intramuscular adipose index (SAI, cm 2 /m 2 ) were calculated using validated methodology (cross sectional area of skeletal muscle/height 2 at L3) from measurement of soft tissue areas on pre- (pre-NC) and post-NC (post-NC) computed tomography. Patients were classified as sarcopenic according to consensus definitions: Male: SMI 2 /m 2 , Female: SMI 2 /m 2 . Pre-NC and post-NC median body mass index (BMI kg/m 2 ), SMI, and adipose indices were compared. Results: The study cohort consisted of 26 patients, with a median age 70 years, including 7 females (27%). Chemotherapy regimens included dose-dense methotrexate, vinblastine, doxorubicin and cisplatin (31%), gemcitabine/cisplatin (62%) and gemcitabine/carboplatin (3.8%) with a median of 3.5 (range 2–6) cycles. Median pre- and post-NC BMI were 27.1 kg/m 2 and 27.2 kg/m 2 ( p = 0.36). Median pre- and post-NC SMI were 49.1 cm 2 /m 2 and 44.5 ( p < 0.001) respectively. Median percent change in SMI was –6.4% (range –30% to 10%). Pre-NC, 18 (69%) patients were sarcopenic vs. 21 (81%, p = 0.002) post-NC. Median time between initiation of chemotherapy and cystectomy was 110 days. Conclusions: We observed a significant decrease in lean muscle mass among MIUC patients treated with platinum-based NC prior to cystectomy, with an associated increase in the prevalence of sarcopenia. Patients undergoing NC may benefit from pre-habilitative interventions to mitigate lean muscle loss prior to cystectomy.Keywords
This publication has 38 references indexed in Scilit:
- Lower skeletal muscle index and early complications in patients undergoing radical cystectomy for bladder cancerWorld Journal of Surgical Oncology, 2014
- Cancer cachexia: impact, mechanisms and emerging treatmentsJournal of Cachexia, Sarcopenia and Muscle, 2012
- Sarcopenia Predicts Early Dose-Limiting Toxicities and Pharmacokinetics of Sorafenib in Patients with Hepatocellular CarcinomaPLOS ONE, 2012
- Sarcopenia as a Prognostic Factor among Patients with Stage III MelanomaAnnals of Surgical Oncology, 2011
- Definition and classification of cancer cachexia: an international consensusThe Lancet Oncology, 2011
- The emerging role of computerized tomography in assessing cancer cachexiaCurrent Opinion in Supportive & Palliative Care, 2009
- Sarcopenia as a Determinant of Chemotherapy Toxicity and Time to Tumor Progression in Metastatic Breast Cancer Patients Receiving Capecitabine TreatmentClinical Cancer Research, 2009
- A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine careApplied Physiology, Nutrition, and Metabolism, 2008
- Age and comorbidity impact surgical therapy in older bladder carcinoma patientsCancer, 2005
- Total body skeletal muscle and adipose tissue volumes: estimation from a single abdominal cross-sectional imageJournal of Applied Physiology, 2004